Johnson & Johnson on August 05 announced its Janssen Pharmaceutical Companies have entered into an agreement with the U.S. government for the large scale domestic manufacturing and delivery in the U.S. of 100 million doses of Janssen’s SARS-CoV-2 investigational vaccine, Ad26.COV2.S, for use in the United States following approval or Emergency Use Authorization by the U.S. Food and Drug Administration (FDA).
The Biomedical Advanced Research and Development Authority (BARDA), in collaboration with the U.S. Department of Defense, is committing over $1 billion for this agreement. The vaccine will be provided at a global not-for-profit basis for emergency pandemic use. The U.S. government may also purchase an additional 200 million doses of Ad26.COV2.S under a subsequent agreement.
“Johnson & Johnson’s global team of experts has worked tirelessly alongside BARDA and scientific partners to pursue a SARS-CoV-2 vaccine that can help to stop the spread of COVID-19″, said Paul Stoffels, Vice Chairman of the Executive Committee and Chief Scientific Officer, Johnson & Johnson.
Johnson & Johnson’s efforts to develop a SARS-CoV-2 vaccine have been undertaken pursuant to an ongoing research and development collaboration with BARDA and under the oversight of the FDA. Based on the positive preclinical data recently published in the peer-reviewed journal Nature, the Phase 1/2a first-in-human clinical trial of the vaccine candidate, Ad26.COV2.S, is underway in healthy volunteers in the United States and Belgium.
The Company is evaluating one- and two-dose regimens, in its clinical program and working diligently to ensure broad, global access to the vaccine following approval or authorization by regulators. Johnson & Johnson aims to meet its goal to supply more than one billion doses globally through the course of 2021, provided the vaccine is safe and effective.
Johnson & Johnson’s SARS-CoV-2 vaccine program leverages Janssen’s AdVac® technology. The same technology was used to develop Janssen’s European Commission-approved Ebola vaccine and construct its HIV, RSV, and Zika vaccine candidates. More than 90,000 individuals have been vaccinated to date using the Janssen AdVac®-based platform.
According to Reuters, there are currently no approved vaccines for COVID-19. More than 20 are in clinical trials and Moderna’s candidate among the farthest along in development.
According to Aljazeera, Moderna announced on July 27 that it had started a late-stage trial to test the effectiveness of its vaccine candidate – the first such trial under Operation Warp Speed and that last hurdle before regulatory approval.
Moderna’s study will test the response to the vaccine in 30,000 adults who do not have the respiratory illness. The company, which has never brought a vaccine to market, has received nearly $1bn from the US government, which has chosen it as one of the first to enter large-scale human trials.
The late-stage trial is designed to evaluate the safety of Moderna’s mRNA-1273 and to determine if the vaccine can prevent symptomatic COVID-19 after two doses. The study also seeks to answer if the vaccine can prevent death caused by COVID-19, and if just one dose can prevent symptomatic COVID-19.
Moderna said it is on track to deliver about 500 million doses a year, and possibly up to one billion doses a year, beginning 2021.
- World breaking news today August 6 Facebook Twitter penalize Trump for posts containing coronavirus misinformation
- WHO issues first emergency use validation to BioNTech-Pfizer COVID vaccine
- Brazil s Bolsonaro rejects China s Covid 19 vaccine
- Top Russian and Chinese COVID 19 vaccines prove potential shortcomings